Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flurbiprofen transdermal - Tokuhon Corporation

Drug Profile

Flurbiprofen transdermal - Tokuhon Corporation

Alternative Names: Fulruban Pap; Stayban® Pap; Yakuban Tape

Latest Information Update: 26 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tokuhon Corporation
  • Developer GC-Rise Pharmaceutical; Taisho Toyama Pharmaceutical; Tokuhon Corporation; Tokyo Medical and Dental University
  • Class Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Inflammatory pain; Muscle pain; Musculoskeletal disorders; Osteoarthritis; Periarthritis; Tendinitis
  • No development reported Pain

Most Recent Events

  • 09 Nov 2018 Taisho Toyama Pharmaceutical and Tokyo Medical and Dental University complete a clinical trial in Osteoarthritis in Japan (PO) (UMIN000024789)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top